Hemogenyx Pharmaceuticals PLC Announces Third Patient Safety

Core Viewpoint - Hemogenyx Pharmaceuticals plc has successfully treated the third patient in its Phase I clinical trial of HG-CT-1 CAR-T therapy for relapsed/refractory acute myeloid leukemia, indicating positive initial safety evaluation results [1] Group 1 - The third patient treated with HG-CT-1 CAR-T therapy has met the predefined initial safety criteria of the trial [1] - The treatment was well tolerated by the patient, suggesting a favorable safety profile for the therapy [1] - The ongoing Phase I clinical trial focuses on adults with relapsed/refractory acute myeloid leukemia [1]